Menopause: The Journal of The North American Menopause Society最新文献

{"title":"Therapeutic efficacy of Yangyin Shugan capsules against premature ovarian insufficiency: results from a multicenter, placebo-controlled trial.","authors":"Xiaojing Cao, Lei Song, Jiarui Hou, Siyu Mao, Qiaolin Du, Fangping Cheng, Daning Feng, Jingyan Zhu, Qiuxia Chen, Xiaoyu Li, Jian Liu, Wenwei Ouyang, Xuchun Huang, Xiaoyun Wang","doi":"10.1097/GME.0000000000002602","DOIUrl":"https://doi.org/10.1097/GME.0000000000002602","url":null,"abstract":"<p><strong>Objectives: </strong>This multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of Yangyin Shugan (YYSG) capsules in women with premature ovarian insufficiency (POI).</p><p><strong>Methods: </strong>This study enrolled 548 Chinese women with POI (August 2016-June 2021) from 13 Guangdong hospitals. After screening, 333 participants were randomized (2:1) to receive YYSG capsules or placebo for 12 weeks. Primary outcomes included the modified Kupperman Index (KI) and serum basal follicle-stimulating hormone, basal E2, and anti-Müllerian hormone levels. Secondary outcomes included psychological status scores (Self-Rating Depression Scale, Self-Rating Anxiety Scale) and ovarian markers (antral follicle count, peak systolic velocity).</p><p><strong>Results: </strong>YYSG demonstrated superior efficacy versus placebo across all endpoints (P < 0.01), including greater reductions in KI scores (-22.2 vs -6.0) and basal follicle-stimulating hormone levels (-23.7 vs -10.4 IU/L) and greater increases in anti-Müllerian hormone levels (2.5 vs 0.8 ng/mL). The YYSG group exhibited larger antral follicle count gains (4.3 vs 1.1 follicles) and bilateral peak systolic velocity improvements (left: 10.8 vs 4.9 cm/s; right: 10.0 vs 4.4 cm/s) and greater reductions in psychological scores (Self-Rating Depression Scale: -12.9 vs -1.3; Self-Rating Anxiety Scale: -15.7 vs -3.7).</p><p><strong>Conclusions: </strong>YYSG capsules significantly improved ovarian reserve function and emotional disorders in women with POI, demonstrating good efficacy and safety. These findings support the potential application of YYSG capsules in clinical practice.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary tract infection symptom management in postmenopausal women: a qualitative exploration.","authors":"Megan Bradley, Amy Irwin, Melanie D Hetzel-Riggin, Chris Shelton, Cameron Macdonald","doi":"10.1097/GME.0000000000002609","DOIUrl":"10.1097/GME.0000000000002609","url":null,"abstract":"<p><strong>Objective: </strong>We sought to complete focus groups with postmenopausal women to discuss their past experiences with urinary tract infections and other lower urinary tract symptoms to source input on how to improve patient care.</p><p><strong>Methods: </strong>We convened 5 focus groups among postmenopausal women with previous experience of treatment for urinary tract infection symptoms. Participants were asked to describe their experiences of urinary symptoms and to make recommendations on how to improve patient education. Three team members read deidentified transcripts of the focus groups, developed a thematic codebook following Conventional Content Analysis guidelines, and coded the data using NVivo software.</p><p><strong>Results: </strong>Twenty postmenopausal women with previous treatment for at least one patient-reported urinary tract infection participated in five focus groups between February and October 2023. The average age of participants was 69.1 (SD 10.8). Three overarching themes emerged from analysis of focus group discussions: (1) barriers to effective care and treatment for urinary tract infections and/or other lower urinary tract symptoms, (2) finding relief via referral and guideline-concordant care, and (3) the physical and emotional cost of unresolved symptoms. While most participants had not found relief, those who did had been referred to a women's urinary health specialist. Once a correct diagnosis was made, real solutions were implemented, ending the cycle.</p><p><strong>Conclusions: </strong>The management of older women with urinary tract infection and lower urinary tract symptoms is currently limited by delays in guideline concordant care. All of the information gathered will help us improve the care of these women.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Being in postmenopause may be associated with lower prevalence of COVID-19 symptoms among women over 45 years of age with and without HIV.","authors":"Emily M Cherenack, Deborah L Jones, Chloe Kaminsky, JoNell Potter, Nicholas F Nogueira, Jaime Dickerson, Mirjam-Colette Kempf, Caitlin A Moran, Michelle Floris-Moore, Elizabeth F Topper, Phyllis C Tien, Seble Kassaye, Howard Minkoff, Anjali Sharma, Helen E Cejtin, Maria L Alcaide","doi":"10.1097/GME.0000000000002618","DOIUrl":"10.1097/GME.0000000000002618","url":null,"abstract":"<p><strong>Objective: </strong>Menopause is associated with COVID-19 severity among women without HIV (WWoH). Yet, little is known about menopause and COVID-19 among women with HIV (WWH).</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of survey data collected in 2020-2022 from WWH and WWoH over 45 years of age enrolled in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study. Women were categorized as premenopausal (no report of menstrual irregularities), perimenopausal (menstruating, with irregularities or self-reported menopause), or postmenopausal (amenorrhea for at least 1 year). Women who reported a positive COVID-19 test in any setting were asked about COVID-19 symptoms. COVID-19 symptoms during the most recent confirmed infection were compared across HIV status and menopause stage.</p><p><strong>Results: </strong>Among 1,244 eligible women (70% WWH), 15% were premenopausal, 9% were perimenopausal, and 76% were postmenopausal. Among 112 women with a prior positive COVID-19 test, HIV status was not associated with COVID-19 symptoms. We combined women across HIV status and compared symptoms during premenopause/perimenopause versus postmenopause. Having any COVID-19 symptom was more common among women in premenopause/perimenopause (89%) than in postmenopause (70%). Compared with women in postmenopause, women in premenopause/perimenopause had higher odds of reporting muscle aches, fatigue, and loss of smell/taste after controlling for HIV, age, race, and ethnicity. When examining premenopause and perimenopause separately and when using alternative criteria to define menopause stage in sensitivity analyses, aches, fatigue, and loss of smell/taste remained least common in postmenopause.</p><p><strong>Conclusions: </strong>COVID-19 symptoms may be least prevalent in postmenopause and may overlap with menopause symptoms in WWH and WWoH.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.","authors":"Shikha Snigdha, Evonne Lau, John Ademola, Robert Frost, Punam Patel","doi":"10.1097/GME.0000000000002608","DOIUrl":"https://doi.org/10.1097/GME.0000000000002608","url":null,"abstract":"<p><strong>Objective: </strong>Menopause is associated with a range of symptoms, including hot flashes, mood swings, and others that adversely affect the quality of life of women. This study evaluated the effects of a novel nutraceutical combination containing γ-aminobutyric acid (GABA, 50 mg) and EstroG-100 (514 mg) on these symptom clusters using validated questionnaires.</p><p><strong>Methods: </strong>Eighty women were randomized into active (age: 53.28) or placebo (age: 52.94) groups. During week 1, participants were instructed to take the product whenever they began to experience vasomotor symptoms as pro re nata dosing (PRN dose, \"as needed\"). For the remainder of the study (weeks 2-5), participants were switched to a daily supplementation phase.</p><p><strong>Results: </strong>Hot flashes decreased in intensity (P = 0.001, starting day 1) and number (P = 0.002, starting day 2) in the active group compared with placebo. Stress response and anxiety also improved as early as day 1, with PRN dosing (P = 0.042). By day 3, there was significant reduction in stress, mood swings and headaches compared with the placebo group (P = 0.010, P = 0.024, and P = 0.008, respectively). In the daily supplementation phase from week 2 to week 5, improvements in vasomotor symptoms (day 7, P = 0.010), sleep quality (5 wk, P = 0.030), feelings of depression (3 wk, P = 0.028), tension (5 wk, P = 0.004), and sexual function (day 7, P = 0.029) were observed in those randomized to the active group compared with placebo.</p><p><strong>Conclusion: </strong>The novel nutraceutical combination of Estro-G100 and GABA may help support women during menopause.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Habitual physical activity and sedentary behavior among women with and without premenopausal bilateral oophorectomy: an exploratory study.","authors":"Omid Jahanian, Stacey J Winham, Ekta Kapoor, Walter A Rocca, Nathan LeBrasseur, Kejal Kantarci, Melissa Morrow, Michelle M Mielke, Emma Fortune","doi":"10.1097/GME.0000000000002574","DOIUrl":"https://doi.org/10.1097/GME.0000000000002574","url":null,"abstract":"<p><strong>Objective: </strong>To explore potential differences in physical activity and sedentary behavior volumes and patterns among postmenopausal women with and without premenopausal bilateral oophorectomy (PBO).</p><p><strong>Methods: </strong>Women with a history of PBO (n = 50) and age-matched postmenopausal referent women (n = 50) were recruited. Participants wore accelerometers on both ankles for 7 days. Volume metrics of sedentary behavior and physical activity, such as step counts, active time, and sedentary time, as well as the sedentary behavior and habitual physical activity distribution, and accumulation patterns, were quantified from the accelerometer data and compared between groups.</p><p><strong>Results: </strong>Metrics indicating volume of sedentary behavior and physical activity were not statistically different between groups. PBO was significantly associated with higher variability in stepping bout time (P = 0.022), indicating a potentially more complex walking pattern. In addition, PBO was significantly associated with lower variability in sedentary break time (P = 0.012), and lower activity time Gini index (Z = -2.428, P = 0.015). This suggests that women with PBO may have broken up their sedentary time with shorter and less variable activity bouts, and because they had relatively shorter average daily active time, they might be at a higher risk of subsequent adverse health outcomes such as low bone mineral density.</p><p><strong>Conclusions: </strong>Although there were no differences in overall activity volume, some differences in activity patterns emerged between women with PBO and referent women. The study highlights the need for longitudinal research to understand how physical activity and sedentary behavior patterns evolve in postmenopausal women with a history of PBO.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depressive symptoms in women with premature ovarian insufficiency (POI): a cross-sectional observational study.","authors":"Charissa van Zwol-Janssens, Yvonne V Louwers, Joop S E Laven, Jits Schipper, Geranne Jiskoot","doi":"10.1097/GME.0000000000002614","DOIUrl":"https://doi.org/10.1097/GME.0000000000002614","url":null,"abstract":"<p><strong>Objective: </strong>To explore associations between clinical and patient-reported variables and depressive symptoms in women with premature ovarian insufficiency (POI).</p><p><strong>Methods: </strong>An exploratory cross-sectional observational study was conducted using data from the center of expertise for women with POI, Erasmus MC, the Netherlands. To identify variables associated with depressive symptoms, as assessed by patient and clinician-reported outcome measures, we used logistic regression models.</p><p><strong>Results: </strong>Between April 2020 and December 2023, 345 women with POI were included. In this cohort, the prevalence of depressive symptoms was 29.9%. No significant difference was found in depressive symptoms between women using estrogen plus progestogen therapy (EPT) (41.7%) and those not using EPT (42.6%, P=0.89). Younger age at diagnosis (P=0.01), POI due to a genetic cause (P=0.04), severe menopausal symptoms (P<0.001), and lack of emotional support (P<0.001) were independently associated with depressive symptoms. The use of EPT or levels of estradiol were not associated with depressive symptoms.</p><p><strong>Conclusions: </strong>The high prevalence of depressive symptoms among women with POI underscores a need for targeted mental health support. Our findings highlight that younger age at diagnosis, severe menopausal symptoms, and fertility-related grief are associated with depression in this population. Given that estradiol levels did not correlate with depressive symptoms, this suggests that psychosocial factors are crucial. Psychological interventions should focus on these factors to address the unique needs of this population.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Playmobil as a creative research tool to explore women's experiences of menopause in the workplace.","authors":"Alison Owen, Jennifer Taylor, Amy Burton","doi":"10.1097/GME.0000000000002599","DOIUrl":"https://doi.org/10.1097/GME.0000000000002599","url":null,"abstract":"<p><strong>Objective: </strong>The present work was designed to explore women's experiences of going through the menopause while working, using Playmobil as a tool for eliciting discussion. A growing body of evidence shows the value of using playful approaches in research; however, very little research has explored the use of Playmobil as a research method.</p><p><strong>Methods: </strong>Research was carried out with 12 co-researchers (aged 31-60) working at a UK university, who were perimenopausal and postmenopausal women. Women attended a workshop and were encouraged to discuss and reflect on their experience of menopause in the workplace using playmobil to facilitate group discussion. The session was audio-recorded.</p><p><strong>Results: </strong>Three themes were developed using Reflexive Thematic Analysis regarding menopause experiences in the workplace: (1) menopause symptoms fundamentally changing experiences of work, (2) symptoms leading to doubts about the ability to work effectively, and (3) ideas for moving forward and improving experiences of menopause in the workplace.</p><p><strong>Conclusions: </strong>Playmobil was a useful method for stimulating discussion. Physical and psychological symptoms of the menopause can have a substantial impact on a person's working life. Workplace settings need to ensure sufficient support is available for employees who are experiencing menopause.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch.","authors":"Mark S Newman, Jaclyn Smeaton","doi":"10.1097/GME.0000000000002542","DOIUrl":"10.1097/GME.0000000000002542","url":null,"abstract":"<p><strong>Objectives: </strong>3,3'-diindolylmethane (DIM) is a supplement, investigational drug, and the primary in vivo product of indole-3-carbinol. DIM is sometimes recommended to postmenopausal women by functional or integrative medicine providers. Some of these women may be concurrently receiving menopausal hormone therapy (MHT), and since DIM's mechanism of action involves the alteration of estrogen metabolism, it is possible that a drug-supplement interaction exists. The objective of this study was to examine the effect of DIM on the estrogen profiles of postmenopausal women receiving MHT in the form of a transdermal estradiol (E2) patch.</p><p><strong>Methods: </strong>This was a retrospective, observational cohort study for which data were collected from a database containing laboratory results for patients processed between January 1, 2016 and December 9, 2019. Laboratory measurements included urinary E2 and 9 other estrogen metabolites. From this database, we identified 1,458 results that were from postmenopausal women using a transdermal E2 patch. Of these 1,458 women, 108 indicated they were concurrently taking a DIM supplement. Wilcoxon rank sum tests were used to assess differences between groups. Multivariable linear regression models were created to confirm the effect of DIM on individual estrogen metabolites.</p><p><strong>Results: </strong>When compared with postmenopausal women using a transdermal E2 patch alone, postmenopausal women using a patch and concurrently taking DIM had statistically significant alterations in their urinary estrogen profiles ( P < 0.001 for all metabolites with differences). Multivariable linear regression models indicated that DIM had a significant effect on 6 of the 10 estrogen metabolites measured, including estrone, estriol, 2-OHE1, 2-OHE2, 4-OHE2, and 16-OHE1, as well as the 2-OHE1/16-OHE1 ratio.</p><p><strong>Conclusions: </strong>Postmenopausal women who are prescribed transdermal E2 patch therapy who choose to concurrently use a DIM supplement may have unexpected changes in their urinary estrogen profiles. Further research is needed to assess whether these changes are clinically significant, as there is a possibility that they may decrease the overall estrogenic impact of MHT on key clinical endpoints such as symptom improvement and bone mineral density. The presence and magnitude of these changes suggest that providers treating postmenopausal women with MHT should ask their patients if they are taking a DIM supplement and, if so, consider the potential implications of drug-supplement interactions for MHT dose management and effectiveness.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"630-639"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical performance of different cervical cancer screening strategies in premenopausal and postmenopausal women.","authors":"Qiang Zhou, Tingyuan Li, Lingling Zhu, Yining Chang, Jingjing Yang, Wen Chen, Ying Yang, Yong He, Chanjuan He, Jingchang Du, Xiaoli Peng, Yuqian Zhao","doi":"10.1097/GME.0000000000002546","DOIUrl":"10.1097/GME.0000000000002546","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluates the clinical performance of high-risk human papillomavirus (HR-HPV) testing, liquid-based cytology (LBC), and HR-HPV and LBC co-testing for detecting cervical intraepithelial neoplasia (CIN) in premenopausal and postmenopausal women.</p><p><strong>Methods: </strong>A total of 6,085 premenopausal and 4,766 postmenopausal women were recruited for cervical cancer screening using LBC and HR-HPV testing. Following screening, colposcopy and biopsy for pathology were performed according to established protocols. We calculated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) for detecting CIN2/3 or worse (CIN2/3+).</p><p><strong>Results: </strong>The sensitivity of LBC for detecting CIN2+ was 73.4% (95% CI=60.7%-83.3%) in premenopausal women and 58.8% (95% CI=44.2%-72.1%) in postmenopausal women. In contrast, significantly higher sensitivities were observed for HR-HPV testing and HR-HPV and LBC co-testing, both of which showed sensitivities of 96.9% (95% CI=88.2%-99.5%) in premenopausal women and 98.0% (95% CI=88.2%-99.9%) in postmenopausal women. While HR-HPV and LBC co-testing demonstrated superior specificity compared with HR-HPV testing alone [95.8% (95% CI=95.2%-96.3%) vs. 86.3% (95% CI=85.4%-87.1%) in premenopausal women; 93.7% (95% CI=92.9%-94.3%) vs. 80.6% (95% CI=79.5%-81.7%) in postmenopausal women], it also exhibited the highest PPV for CIN2+ prediction [19.6% (95% CI=15.4%-24.4%) in premenopausal women; 14.5% (95% CI=10.9%-18.6%) in postmenopausal women] compared with LBC or HR-HPV testing alone.</p><p><strong>Conclusions: </strong>HR-HPV and LBC co-testing demonstrates comparable high clinical accuracy for detecting CIN2+ in both premenopausal and postmenopausal women, with a preference for its use in postmenopausal screening.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"640-647"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letters to the Editor.","authors":"Sarah Glynne","doi":"10.1097/GME.0000000000002582","DOIUrl":"10.1097/GME.0000000000002582","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"667-669"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}